Are ‘super donors’ the answer to sustainable growth for the allogeneic cell and gene therapy industry?
Why reliance on a small subset of donors could introduce risk for companies
An expert opinion on HLA matching relevance for allogeneic cell therapies
By Jamie Margolis, PhD, Senior Vice President of Donor Services, NMDP/Be The Match
Q&A with the Be The Match BioTherapies Collection Network Liaison team
As told by Leah, Be The Match BioTherapies® allogeneic donor
On-demand webinar available